STUDY OF THE GENERAL TOXIC PROPERTIES OF THE ANTI-TB DRUG THIOSONIDE
https://doi.org/10.36946/0869-7922-2021-1-47-51
Abstract
The aim of the study was to evaluate the subchronic and chronic toxicity of the substance – thiosonide - in experiments on rabbits and rats. The animals received doses ranging from therapeutic to 75 times higher. The drug in studied doses did not cause any significant changes in body weight increase of animals, behavioral reactions, food and water consumption. There were no changes in the biochemical and cellular composition of peripheral blood, the protein-synthesizing function of the liver, carbohydrate metabolism, and the functional state of the cardiovascular system. In the work of the central nervous system, a slight decrease in motor activity was observed in male rats that were long-term treated with a drug substance in a dose of 100 mg/kg (more than 10 times higher than the therapeutic dose). A local irritant effect in the gastrointestinal tract of experimental rats was noted according to the results of histological studies, most pronounced under the influence of the drug at a dose of 100 mg/kg. According to the results of histological studies, minor dystrophic changes in the liver, kidneys and myocardium were found in some animals under the influence of a drug substance at a dose of 100 mg/kg. Thus, the active substance of the anti-tuberculosis drug does not have toxic properties that limit its long-term use, which allows us to consider it as a promising tool for inclusion in the basic long-term courses of treatment of the disease.
About the Authors
A. Yu. Savchenko
Scientific Center of Biomedical Technology of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Savchenko Аlla Yuryevna
143442, Svetlye Gory Village, Krasnogorsk District, Moscow region
М. S. Burenkov
Joint-Stock Company «Pharm-Sintez»
Russian Federation
Russian Federation
Burenkov Mikhail Sergeevich
111024, Moscow
Р. S. Baidin
Joint-Stock Company «Pharm-Sintez»
Russian Federation
Russian Federation
Baidin Petr Sergeevich
111024, Moscow
G. V. Ramenskaya
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Ramenskaya Galina Vladislavovna
119991, Moscow
V. G. Kukes
Clinical Pharmacology Branch of the Scientific Center of Biomedical Technology of the Federal Medical and Biological Agency
Russian Federation
Russian Federation
Kukes Vladimir Grigorievich
109240, Moscow
References
1. Uplekar M., Weil D., Lonnroth K., Jaramillo E., Lienhardt C., Dias H.M., ... &Gilpin C. WHO’s new end TB strategy. Lancet, 2015, vol. 385. pp. 1799 – 1801.
2. Esposito S, D’Ambrosio L, Tadolini M, Schaaf HS, Caminero Luna J, Marais B, Centis R, Dara M, Matteelli A, Blasi F, Migliori GB. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal. 2014; 44: pp. 811–815
3. Marisa K, Robin Mark W, Cindy H, Nicolaas Claudius Gey van P, Elizabeth Maria S, Borna M, Frederick Adriaan S, Mamisa CN, Ebrahim H, Gerrit C, Paul David van H, Thomas Calldo V, André Phillip T. Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa. Emerging Infectious Disease journal. 2013; 19: 449.
4. Vasil’eva I.A., Belilovskij E.M., Borisov S.E., Sterlikov S.A. Morbidity, mortality and prevalence as indicators of the burden of tuberculosis in WHO regions, countries of the world and in the Russian Federation. Part 1. Tuberculosis incidence and prevalence. Tuberculosis and lung disease. 2017; 95 (6): 9-21 (in Russian).
5. Global Tuberculosis Report 2018: WHO/HTM/TB/2018.20– Geneva: WHO, 2018.
6. Filinyuk O.V., Fel’ker I.G., Yanova G.V., Bujnova L.N., Kolokolova O.V. Risk factors for ineffective chemotherapy for multidrug-resistant tuberculosis patients. Tuberculosis and lung disease. 2014, 1, 20-26 (in Russian).
7. Shchegertsov D.Yu., Filinyuk O.V., Bujnova L.N., Zemlyanaya N.A., Kabanec N.N., Alliluev A.S. Undesirable adverse reactions in the treatment of patients with multidrug-resistant tuberculosis of the pathogen. Tuberculosis and lung disease. 2018;96 (3): 35-43 (in Russian).
8. Men’shikova L.A. Pharmacokinetic study of the original drug thiosonide: Kand. pharm. sci. diss., Moscow, 2016 (in Russian).
9. Bocharova I.V., Burenkov M.S., Lepekha L.N., Smirnova T.G., Hernousova L.N., Demihova O.V. Preclinical studies of the specific activity of the new anti-TB drugthiosonide. Tuberculosis and lung disease. 2014; (6): 46-50 (in Russian).
10. Freireich E., Karon M., Frei E. Quadruple combination therapy (VAMP) for acute limphocytic leukemia of childhood. Proc. Am. Ass.Cancer Res. - 1964. - Vol.5. - P.20.
11. Guidelines for preclinic.al studies of drugs. Part one. - M.: Grif and K, 2012, 944 p (in Russian).
12. Borovikov V.P. Borovikov I.P Statistical analysis and data processing in Windows – M.: Filin, 1997, 608 p. (in Russian).
13. Harris M. Medical statistics made easy / M. Harris, G. Taylor. – London: Taylor and Francis, 2006.
Review
For citations:
Savchenko A.Yu., Burenkov М.S., Baidin Р.S., Ramenskaya G.V., Kukes V.G. STUDY OF THE GENERAL TOXIC PROPERTIES OF THE ANTI-TB DRUG THIOSONIDE. Toxicological Review. 2021;1(1):47-51. (In Russ.) https://doi.org/10.36946/0869-7922-2021-1-47-51
Views:
730
Email this article 